+171.0%
CPRT vs MRNA
+516.4%
-345.4%
-57.4%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -1.7% | -3.4% | +1.6% | -1.6% |
| 7D | -0.4% | -10.1% | +9.7% | +0.1% |
| 30D | +8.2% | +126.7% | -118.5% | +0.1% |
| 3M | +2.3% | +184.1% | -181.8% | -6.8% |
| 6M | -14.7% | +143.3% | -158.0% | -21.8% |
| YTD | -18.2% | +359.9% | -378.0% | -27.8% |
| 1Y | -33.4% | +454.2% | -487.6% | -42.1% |
| 3Y | -28.3% | +26.0% | -54.3% | -33.8% |
| 5Y | -9.8% | -70.3% | +60.4% | -14.5% |
| All | +171.0% | +516.4% | -345.4% | +145.9% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling